Skip to main content

Table 3 Clinical trials of chimeric antigen receptor T-cell therapy for B-cell lymphoma

From: Advances in chimeric antigen receptor T-cell therapy for B-cell non-Hodgkin lymphoma

NCT Numberb Conditionso Interventiont P Phase h Number Dose D Outcomes O
NCT04169932 R/R B-cell lymphoma; NHL CD20 CAR-T Early phase I 20 (1, 2, 4, 8) × 10^6 cells/kg NR
NCT03994913 R/R B-NHL CD19 CAR-T Phase I
Phase II
78 NR NR
NCT04036019 B-cell lymphoma CD20 CAR- T Phase I 12 NR NR
NCT04429438 B-cell lymphoma 4SCAR19 and 4SCAR20/22/70/PSMA/13/79b/GD2 Phase I
Phase II
11 NR NR
NCT04381741 DLBCL CD19 CAR-T plus PD1 monoclonal antibody Phase I 24 (1, 2, 3)×
10^6 cells/kg plus 200 mg Tislelizumab every 3 weeks for 6 times
NR
NCT04260932 B-cell lymphoma CD19/CD20 Dual- CAR-T Phase I 12 Escalated dose of (1–6) × 10^6 cells/kg NR
NCT03929107 B-cell lymphoma IL-7 and chemokine ligand 19-expressing CD19-CAR-T cells Phase II 80 NR NR
NCT03854994 B-cell lymphoma; B-ALL CD19 CAR-T Cells Phase I 10 (1–5) × 10^6 cells/kg NR
NCT04316624 DLBCL C-CAR066 Phase I 10 Low: (1.0–3.0) × 10^6 cells/kg;
Medium: (3.0–6.0) × 10^6 cells/kg;
High: (6.0–9.0) × 10^6 cells/kg
NR
NCT04240808 NHL UCD19 CAR T Cells Phase I 20 NR NR
NCT04539444 R/R NHL CD19/22 CART Phase II 20 3-day split-dose regimen at dose of (0.5–2) × 10^6 cells/kg NR
NCT03881761 B-cell lymphoma CD19/CD20 bispecific CAR-T Phase I 50 (1–3) × 10^6 cells/kg NR
NCT04486872 DLBCL Autologous humanized CD19/CD20 bispecific CAR-T Phase I 18 1.00 × 10^6 cells/kg, 3.00 × 10^6 cells/kg or 5.00 × 10^6 cells/kg NR
NCT04257578 B-NHL; DLBCL; High grade B-cell lymphoma; PMBCL; tFL Axicabtagene Ciloleucel Phase I
Phase II
20 NR NR
NCT03391726 B-cell lymphoma CD19 CAR-T Phase II 20 NR NR
NCT04416984 B-cell lymphoma ALLO-647 Phase I
Phase II
120 NR NR
NCT03103971 B-ALL; DLBCL; PMBL; R/R B-NHL CD19 CAR-T Phase I 73 NR NR
NCT03287817 DLBCL;
R/R DLBCL
AUTO3 Phase I
Phase II
171 (50–900) × 10^6 cells NR
NCT04049513 B-NHL; DLBCL; PMBCL; tFL; FL; MCL WZTL002–1 Phase I 12 Starting dose of 5 × 10^4 cells/kg NR
NCT04432506 R/R DLBCL; R/R high grade B-cell lymphoma; R/R PMBCL; R/R tFL Axicabtagene Ciloleucel Phase I 20 NR NR
NCT04532268 ALL; B-NHL Humanized CD19 CAR-T cells Early phase I 72 NR NR
NCT03932955 Lymphoma MC-19PD1 CAR-T cells Phase I 15 NR NR
NCT04191941 B-NHL; B-ALL; MM Novel CAR-T Phase I 9 NR NR
NCT04007029 CLL; R/R DLBCL; FL; MCL; PMBCL; SLL CAR-T Phase I 24 NR NR
NCT04163302 B-cell lymphoma CD19-PD1-CAR-T Cell Phase II 30 NR NR
NCT04215016 R/R DLBCL Patients With Either CD19 or CD20 Positive Autologous humanized CD19/CD20 bispecific CAR-T Phase I 18 The first dose is 1.0 × 10^6 cells/kg, the second dose is 3.0 × 10^6 cells/kg and the third dose is 8.0 × 10^6/kg. NR
NCT03664635 R/R B-NHL MB-CART20.1 Phase I
Phase II
19 Safety dose level: 1 × 10^5 cells/kg;
Dose level 1: 1 × 10^6 cells/kg;
Dose level 2: 3 × 10^6 cells/kg.
NR
NCT04088890 B-ALL; B-NHL; DLBCL CD22 CAR-T Phase I 95 ALL: 3 × 10^5 cells/kg(±20%); B-NHL: 1 × 10^6 cells/kg, 3 × 10^6 cells/kg and 1 × 10^7 cells/kg NR
NCT03366324 ALL;
B-cell lymphoma
Second generation CAR-T cells Phase I
Phase II
20 NR NR
NCT03277729 R/R B-NHL; CLL; R/R DLBCL; Recurrent FL; Recurrent MCL; Recurrent MZL CAR-T Phase I
Phase II
30 NR NR
NCT04532281 ALL; NHL CD19 CAR-T Early phase I 120 NR NR
NCT03398967 B-cell lymphoma Dual specificity CD19 and CD20 or CD22 CAR-T Cells Phase I
Phase II
80 NR NR
NCT02965092 ALL;
B-cell lymphoma
Second generation CAR-T cells Phase I
Phase II
80 (0.89–4.01) × 10^6 CAR-T cells/kg Median overall survival (OS) was 16.1 months. The 6-month and 12-month OS rates were 69.727 and 64.028%.
NCT02963038 B-cell lymphoma Autologous CD19- targeting CAR T Phase I
Phase II
10 NR NR
NCT03383952 B-cell lymphoma ICAR19 CAR-T cells Phase I 20 NR NR
NCT04007978 B-cell lymphoma; ALL Third generation CAR- T Phase I 50 NR NR
NCT04532203 ALL; NHL CAR-T cells Early phase I 72 NR NR
NCT04603872 R/R MM; R/R ALL; R/R NHL CD19/BCMA CAR T-cells Early phase I 120 NR NR
NCT03939026 R/R Large B-Cell Lymphoma; R/R FL ALLO-647 Phase I 54 NR NR
NCT04008251 ALL;
B-cell lymphoma
Second generation humanized CAR-T Phase I 10 NR NR
NCT03118180 Lymphoma CD19 CAR-T Phase I
Phase II
50 NR NR
NCT02650414 B-cell lymphoma CD22 CAR-T Phase I 15 Subjects < 50 kg: (0.2–1) × 10^7 cells/kg
Subjects > 50 kg: (1–5) × 10^8 cells
NR
NCT04317885 B-NHL CD19/CD20-directed CAR-T cells Phase I 25 NR NR
NCT03166878 B-cell lymphoma UCART019 Phase I
Phase II
80 Day 0: 10% of total dose. Day 1: 30% of total dose if patient is stable. Day 2: 60% of total dose if patient is stable. NR
NCT03720457 DLBCL; FL CD19 CAR-T Phase I 18 NR NR
NCT03559439 B-cell lymphoma; B-ALL CD19 CAR T Phase I 9 Low: 1 × 10^5 cells/kg; Medium: 2 × 10^6 cells/kg; High: 6 × 10^6 cells/kg NR
NCT04088864 B-cell lymphoma; ALL Autologous CD22 CAR T Phase I 52 R/R B-ALL: 1 × 10^6 cells/kg (±20%).
Lymphoma: 1 × 10^6 cells/kg (±20%).
NR
NCT03696784 B-cell lymphoma iC9-CAR19 T cells Phase I 30 (1–2) × 10^6 cells/kg NR
NCT04204161 R/R ALL;
B-cell lymphoma
CAR-T19/CAR-T22 Phase I 30 The recommand dose: 1 × 10^5/kg-2.5 × 10^8/kg NR
NCT03853616 ALL;
B-cell lymphoma; R/R CLL
MB-CART19.1 Phase I
Phase II
48 × 10^5/kg-3 × 10^6/kg NR
NCT03881774 B-cell lymphoma CAR-T cells Phase I 20 (0.5–3) × 10^6/kg NR
NCT04176913 DLBCL; FL; MCL; SLL LUCAR-20S CAR-T cells Phase I 41 NR NR
NCT04156243 B-cell lymphoma CD19 CAR T cells Early phase I 20 NR NR
NCT04089215 NHL; DLBCL; FL CD19 CAR-T Phase II 82 1.0 × 10^8 and 1.5 × 10^8 cells Three month ORR: 60.3%
NCT04205838 DLBCL; High grade B-cell lymphoma; R/R tFL; R/R PMBCL Axicabtagene Ciloleucel Phase II 36 NR NR
NCT04464200 DLBCL; PMBCL;
tFL; CLL; MZL; WM; Burkitt’s lymphoma; Primary CNS lymphoma
19(T2)28z1xx CAR T cells Phase I 60 Planned flat-dose levels: (25, 50, 100, 150, 200) × 10^6 cells;
De-escalation dose: 12.5 × 10^6 cells.
NR
NCT04545762 Refractory NHL; Burkitt lymphoma; MCL; FL; PMBCL;
DLBCL; SLL
CD19 CAR-T cells Phase I 36 Starting dose: 5 × 10^5 cells/kg NR
NCT03999697 DLBCL; FL; MCL; Plasma cell neoplasm CD22 CAR-T Phase I 10 NR NR
NCT04214886 B-ALL;
B-cell lymphoma
CD19-CD34 CAR-T Phase I 24 × 10^6 cells/kg (± 20%) to 2 × 10^6 cells/kg NR
NCT03666000 NHL; B-ALL PBCAR0191 Phase I
Phase II
92 Starting dose: 3 × 10^5 cells/kg;
Subsequent dose groups: escalating doses to a maximum dose of 9 × 10^6 cells/kg.
NR
NCT02772198 B-ALL; B-NHL CD19 CAR T cells Phase I
Phase II
300 NR ORR was 84% (30/36) in ALL and 62% (32/52) in NHL.
NCT04156178 B-cell lymphoma CD20-CD19 CAR-T Early phase I 12 NR NR
NCT03743246 Precursor cell lymphoblastic leukemia- lymphoma; B-cell lymphoma JCAR017 Phase I
Phase II
121 0.05 × 10^6–0.75 × 10^6 cells/kg NR
NCT03676504 ALL; CLL; DLBCL; FL; MCL CD19 CAR T Cells Phase I
Phase II
48 × 10^6 cells/m^2 to 20 × 10^7 cells/m^2 NR
NCT03448393 ALL;
B-cell lymphoma; B-NHL
CD19/CD22 CAR T- Cells Phase I 89 × 10^5 cells/kg (+/− 20%); 3 × 10^5 cells/kg (+/− 20%); 1 × 10^6 cells/kg; 3 × 10^6 cells/kg (+/− 20%); 1 × 10^7 cells/kg (+/− 20%). NR
NCT04186520 B-NHL; MCL CAR-T Phase I
Phase II
32 2.5 × 10^6 cells/kg NR
NCT02631044 NHL; DLBCL; FL; MCL; PMBCL JCAR017 Phase I 314 50 × 10 CAR-T cells [one or two doses], 100 × 10 CAR-T cells, and 150 × 10 CAR-T cells. ORR was 73% and CR rate was 53% among 256 patients with B-NHL.
NCT03744676 B-NHL;
B-cell lymphoma;
DLBCL
lisocabtagene maraleucel Phase II 80 NR NR
NCT02706405 DLBCL; PMBCL JCAR014 Phase I 42 NR NR
NCT04226989 ALL; NHL CT-RD06 Early phase I 72 NR NR
NCT04314843 B-cell lymphoma Axicabtagene Ciloleucel Phase I
Phase II
36 NR NR
NCT03497533 B-NHL TriCAR-T-CD19 Phase I
Phase II
6 (0.5–1) × 10^6 CAR-T cells/kg NR
NCT03720496 B-NHL CD19-TriCAR-T Phase I 6 (0.1–1) × 10^6 cells/kg NR
NCT03105336 FL; MZL; Indolent NHL Axicabtagene ciloleucel Phase II 160 NR NR
NCT03310619 NHL; DLBCL; FL JCAR017 Phase I
Phase II
75 50 × 10^6 CAR-T cells; 100 × 10^6 CAR-T cells. NR
  1. Abbreviations: CAR chimeric antigen receptor, ORR objective response rate, CR complete response, DLBCL diffuse large B-cell lymphoma, B-ALL B-cell acute lymphoblastic leukemia, NHL non-Hodgkin lymphoma, B-NHL B-cell non-Hodgkin lymphoma, R/R B-NHL refractory/relapsed B-cell non-Hodgkin lymphoma, PMBCL primary mediastinal large B-cell lymphoma, FL follicular lymphoma, tFL transformed follicular lymphoma, R/R tFL refractory/relapsed transformed follicular lymphoma, MCL mantle cell lymphoma, MM multiple myeloma, SLL small lymphocytic lymphoma, CLL chronic lymphocytic leukemia, MZL marginal zone lymphoma, WM Waldenstrom macroglobulinemia